Gilead and Merck Release Key HIV Data on July 22, 2026 Acquired Immunodeficiency Syndrome Biological Science Disciplines CROI Funds Gilead healthcare innovation HIV Islatravir/lenacapavir Lenacapavir Merck R&D +
Trodelvy misses lung cancer endpoint, but Gilead and Merck score HIV win with weekly combo on June 09, 2026 EVOKE-03 trial Gilead Merck HIV islatravir Keytruda combo Lenacapavir Malignant neoplasm of lung once-weekly Success Trodelvy +
WHO to Develop Guidelines for Gilead's Twice-Yearly HIV PrEP Injection (Lenacapavir) on July 14, 2025 Approved Gilead Guidelines HIV prevention Lenacapavir PREP gene twice-yearly injection United States Food and Drug Administration World Health Organization +
Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot on June 20, 2025 Approved Gilead Guidelines HIV prevention Lenacapavir long-acting injectable PREP gene twice-yearly injection United States Food and Drug Administration World Health Organization Yeztugo +
FDA Approves Gilead's Twice-Yearly HIV Prevention Shot on June 19, 2025 Approved Gilead Sciences HIV prevention Lenacapavir PREP gene public health medicine (field) twice-yearly injection United States Food and Drug Administration Yeztugo +
FDA Places Clinical Hold on Five Gilead HIV Studies Due to Safety Concerns on June 11, 2025 Biktarvy CD4 + T-cell Clinical Trials Gilead Sciences GS-1720 GS-4182 HIV Lenacapavir Lymphocyte Count measurement safety signal Study on Hold United States Food and Drug Administration +
Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch on April 25, 2025 Gilead HIV prevention launch Lenacapavir long-acting Pre-Exposure Prophylaxis U.S. United States Food and Drug Administration +
Gilead Sciences Prepares for Summer 2025 Launch of Long-Acting HIV Prevention Drug Lenacapavir on February 14, 2025 Approved Clinical Trials Gilead Sciences HIV prevention HIV sales Lenacapavir PREP gene PURPOSE studies United States Food and Drug Administration +
Battle for HIV PrEP Market: Gilead's Twice-Yearly Injection Challenges GSK's Apretude on February 07, 2025 Apretude HIV prevention Lenacapavir long-acting injectables PREP gene SmithKline Beecham ViiV Healthcare +